Author: The INO.com Team

Global EV Demand Soars: Why Tesla (TSLA) Could Be a Must-Buy in 2025

Posted on by The INO.com Team

The electric vehicle (EV) industry is witnessing unprecedented growth, driven by global policy shifts, increasing consumer demand, and advances in technology. According to the International Energy Agency (IEA), global EV sales surged past 17 million units in 2024, a 25% increase from the previous year. With governments worldwide implementing aggressive policies to phase out internal combustion engines (ICEs), the transition to EVs is accelerating.

Tesla, Inc. (TSLA), the undisputed leader in the EV space, continues to ride this wave, reporting record production and deliveries in 2024. The company’s strong financial performance, expanding manufacturing capacity, and technological advancements make it a compelling investment for 2025. Moreover, Tesla’s ability to scale production while maintaining healthy profit margins has positioned it as a dominant force in the global EV industry, attracting both institutional and retail investors.

Key Developments Driving EV Demand

Several key markets have introduced favorable policies to support EV adoption. In the United States, the Inflation Reduction Act continues to provide substantial tax credits for EV buyers, with Tesla benefiting from the $7,500 federal EV incentive. In the European Union, the commitment to banning new ICE vehicle sales by 2035 has propelled EV demand, with Tesla’s Model Y leading sales in several European countries. Meanwhile, China’s aggressive subsidies and support for domestic production have solidified EVs as mainstream vehicles, helping Tesla gain significant traction in this crucial market.

Tesla has consistently maintained a dominant market share in key regions. In Q3 2024, Tesla delivered 462,890 vehicles, marking a 6% year-over-year increase. The Model Y became the best-selling vehicle in Europe in September 2024, underscoring the increasing consumer preference for EVs over traditional gasoline-powered cars. In China, Tesla’s Shanghai Gigafactory achieved a milestone by producing its 3-millionth vehicle, demonstrating its ability to scale manufacturing efficiently. This strong momentum reflects the broader consumer shift toward sustainable transportation solutions.

Tesla’s Competitive Edge

Tesla’s innovation in battery efficiency, AI-powered autonomy, and charging infrastructure continues to outpace competitors. The company’s cost of goods sold (COGS) per vehicle dropped to a record-low $35,100, improving profit margins. Full Self-Driving (FSD) technology is rapidly advancing, with over 2 billion miles driven using FSD (Supervised). The latest V12 software makes significant strides toward autonomous capability, which could revolutionize urban mobility. Additionally, Tesla’s Supercharger network expanded by 22% year-over-year, reinforcing its dominance in EV infrastructure and alleviating consumer concerns about charging accessibility.

Tesla’s production capacity has expanded significantly, enabling it to meet growing demand. The Texas Gigafactory ramped up Cybertruck production, with deliveries beginning in late 2024. The Berlin Gigafactory’s Model Y became the best-selling EV in multiple European countries, further strengthening Tesla’s foothold in the European market. Meanwhile, Tesla’s Shanghai factory produced and exported over 1 million vehicles in 2024, underscoring its importance to global operations. These developments highlight Tesla’s ability to execute large-scale production while maintaining operational efficiency.

Investment Analysis

Tesla stock’s nearly 70% returns over the past six months reflect its financial strength. The company’s Q3 2024 revenue reached $25.2 billion, an 8% year-over-year increase. Net income (GAAP) surged 17% year-over-year to $2.2 billion, signaling strong profitability. The company holds $33.6 billion in cash reserves, providing ample liquidity for future growth. These financial indicators suggest Tesla’s ability to weather economic downturns while continuing to invest in innovation and expansion.

Several analysts have recently upgraded Tesla’s stock, citing strong vehicle deliveries and robust demand in international markets. Advancements in AI and autonomous technology are expected to be potential future revenue drivers. Tesla’s diversification into energy storage has also been a significant growth factor, with revenue from energy storage increasing by 52% in Q3 2024. However, investors should be aware of potential risks, including supply chain constraints, increased competition from rivals such as BYD and Rivian (RIVN), and regulatory uncertainties that may impact future demand.

What Investors Should Do

Tesla’s trajectory aligns with long-term growth trends in the EV industry. With record deliveries, a strong balance sheet, and continued innovation in AI and battery technology, Tesla remains a compelling investment for 2025. Investors looking for exposure to the rapidly expanding EV market should consider Tesla as a strong ‘Buy’ candidate. However, those concerned about valuation and volatility may opt to watch for potential pullbacks before entering a position. Given Tesla’s continued leadership in the EV industry and its aggressive expansion into new markets, it remains a stock to closely monitor for long-term gains.

Autonomous Vehicles on the Horizon: Why Luminar Technologies (LAZR) Could Light the Way

Posted on by The INO.com Team

Autonomous vehicles (AVs) are no longer a futuristic concept; they are steadily becoming a reality. Automakers and tech firms are aggressively developing self-driving systems, with lidar—a laser-based sensor technology—playing a central role in ensuring safe and reliable automation. Luminar Technologies, Inc. (LAZR), a leader in high-performance lidar solutions, has positioned itself as a key enabler in this transition.

In Q3 2024, Luminar expanded its business by securing additional partnerships with global automakers, including Volvo and a major Japanese manufacturer. With the increasing adoption of its sensors and software, the company is gaining traction in an industry that is projected to grow at a CAGR of 41.6% from $1.19 billion in 2024 to reach $9.59 billion by 2030. Governments worldwide are also beginning to mandate stricter safety features in vehicles, creating an even more favorable environment for lidar adoption. As competition heats up in the AV sector, Luminar’s technology may serve as a key differentiator for automakers striving to meet new regulatory standards and consumer expectations.

The Role of Lidar in Autonomous Mobility

Lidar is critical for AVs because it provides high-resolution, three-dimensional mapping of the surrounding environment, enabling better object detection and navigation. Unlike camera and radar-based systems, which can struggle with depth perception and adverse weather conditions, lidar enhances safety by offering precise distance measurements and obstacle detection.

Automakers are increasingly integrating lidar into their advanced driver-assistance systems (ADAS). Notably, Volvo has made Luminar’s lidar a standard feature in the EX90, reinforcing the industry's shift toward enhanced safety protocols. As regulatory frameworks tighten globally, particularly in Europe and the U.S., the demand for lidar technology is set to rise. Additionally, the insurance industry is beginning to recognize the safety benefits of lidar-equipped vehicles, which could lead to lower premiums for consumers and further incentivize automakers to adopt the technology.

Luminar Technologies: A Rising Leader in Lidar

Luminar’s growing influence is evident through its expanding relationships with major automakers. The company secured a new agreement with a leading Japanese automaker, extending collaboration on next-generation ADAS. This follows its well-publicized deal with Volvo, where Luminar’s lidar is a cornerstone technology in Volvo’s pursuit of zero-fatality vehicles.

Beyond Volvo, Luminar has previously inked agreements with Mercedes-Benz, Nissan, and Polestar, underscoring its broad industry appeal. These partnerships suggest increasing adoption of its lidar sensors as automakers shift toward Level 3 and beyond autonomous capabilities. Furthermore, the company’s commitment to innovation is reflected in its next-generation Luminar Halo system, which promises improved performance at a lower cost, making mass adoption more feasible.

While Luminar reported Q3 2024 revenue of $15.5 million, slightly down from Q2, it saw a significant improvement in cash flow due to cost-saving measures. The company implemented restructuring actions that are projected to save approximately $80 million annually, helping to improve operational efficiency. In terms of production scale, Luminar ramped up shipments of its lidar sensors in Q3, surpassing the total output of the previous three-quarters combined. With its newly launched TPK facility, the company aims to optimize manufacturing costs further while maintaining its technological edge. As the industry moves toward larger-scale adoption, the ability to scale production efficiently will be crucial for maintaining a competitive edge.

Investment Risks: Competition and Market Uncertainty

Despite Luminar’s advancements, the lidar market is highly competitive. Companies like Velodyne, Innoviz (INVZ), and Ouster are vying for market share, while Tesla, Inc. (TSLA) remains committed to a camera-based AV approach. Additionally, some industry players are exploring radar-lidar hybrid solutions, which could shift market dynamics. The pace of regulatory changes and varying levels of government support for AV technology also add an element of uncertainty that investors should consider.

Financially, while Luminar is reducing costs, it remains unprofitable, reporting a net loss of $0.24 per share in Q3 2024. The company’s ability to achieve sustained profitability will depend on continued revenue growth and successful cost optimization. Furthermore, the overall AV industry has yet to reach mass adoption, and delays in regulatory approvals or consumer acceptance of self-driving technology could slow down Luminar’s growth trajectory. Investors should also be mindful of the company’s reliance on automaker partnerships, as shifts in industry strategy or economic downturns could impact future contracts.

Should Investors Consider Luminar?

For investors seeking exposure to the autonomous driving sector, Luminar presents a compelling opportunity. Its strategic partnerships, technological leadership, and improving financial efficiency suggest strong long-term potential. However, risks remain, particularly in a highly competitive and evolving market. The company’s ability to maintain its first-mover advantage while managing financial sustainability will be key factors in determining its long-term success.

LAZR stock has shown volatility, making it a higher-risk, higher-reward investment. Investors bullish on lidar adoption and the autonomous vehicle revolution may see Luminar as a strong bet, while those with a lower risk tolerance may prefer to monitor the company’s path to profitability before committing capital. Additionally, long-term investors who believe in the growth of AV technology may consider accumulating shares during market dips, as lidar adoption trends appear to be gaining momentum. As the industry evolves, Luminar’s ability to execute on its expansion strategy and maintain strong relationships with automakers will be crucial in determining its future trajectory.

AI in Healthcare: Why Schrodinger (SDGR) Could Transform Drug Discovery

Posted on by The INO.com Team

Artificial intelligence (AI) is revolutionizing the pharmaceutical industry by making drug discovery faster, more efficient, and cost-effective. Traditionally, drug development is a lengthy and expensive process, often taking over a decade and costing billions of dollars. AI is changing this landscape by enabling computational modeling to predict molecular interactions, optimize drug candidates, and reduce trial-and-error experimentation.

One of the leaders in this space is Schrodinger, Inc. (SDGR), a company that has built a physics-based computational platform for drug discovery. Schrodinger’s software leverages AI and molecular simulations to accelerate the identification of promising compounds. As AI adoption in healthcare grows, Schrodinger’s technology could become an integral part of modern drug R&D. The company’s ability to integrate AI with physics-based modeling distinguishes it from other players in the space, making it a pioneer in digital-first drug discovery.

The increasing reliance on AI in pharmaceutical research is also being driven by regulatory bodies and policymakers who recognize the need for more efficient drug development. The FDA, for example, has shown interest in AI applications for drug discovery, providing a favorable environment for companies like Schrodinger. As regulatory support grows, the acceptance of AI-powered drug development could become more widespread, benefiting Schrodinger and similar companies.

Investment in AI-Driven Healthcare Solutions

The pharmaceutical sector has seen a surge in investments in AI-based solutions. According to CB Insights, funding for AI-driven drug discovery startups exceeded $3 billion in 2024 (as of 12/09/2024), up 43% from the 2023 level. Major pharmaceutical firms are increasingly partnering with AI firms to enhance their drug pipelines.

Big pharmaceutical companies such as AstraZeneca (AZN), Novartis (VVS), and Bristol-Myers Squibb (BMY) have invested heavily in AI-driven drug discovery partnerships. These investments indicate a long-term shift towards computational-first drug discovery, reducing dependency on traditional, high-cost laboratory experiments. AI is not just expediting drug discovery but also optimizing clinical trial processes, leading to better patient stratification and higher success rates in drug approvals.

The global AI in the drug discovery market is expected to grow at a CAGR of 29.7% from 2024 to 2030. The rapid expansion of this market reflects strong demand for computational approaches in drug research. With AI reducing both costs and development timelines, traditional pharmaceutical research is transitioning toward digital-first approaches. This transformation presents a significant opportunity for Schrodinger, whose platform is designed to facilitate AI-driven pharmaceutical R&D.

Schrodinger’s Platform for Computational Drug Discovery

Schrodinger combines physics-based simulations with AI and machine learning to enhance drug discovery processes. Its proprietary Free Energy Perturbation (FEP+) technology allows scientists to accurately predict the binding affinity of drug candidates, significantly improving hit-to-lead and lead optimization phases.

In Q2 2024, Schrodinger reported $35.4 million in software revenue, a 21% year-over-year increase. The company’s software revenue has grown consistently, indicating strong adoption among pharmaceutical firms. In addition to software, Schrodinger’s drug discovery partnerships generated $11.9 million in Q2 revenue, reflecting a 104% increase from the previous year. These numbers highlight the growing acceptance of AI-driven drug discovery and the company’s ability to monetize its platform through partnerships and licensing agreements.

Schrodinger is also actively developing its own drug candidates. Its proprietary therapeutics pipeline includes SGR-1505 (a MALT1 inhibitor) and SGR-2921 (a CDC7 inhibitor), both of which are expected to yield Phase 1 clinical data in 2025. The company’s ability to leverage its computational tools for in-house drug development adds another layer of potential value. Additionally, Schrodinger has received a $10 million grant from the Bill & Melinda Gates Foundation to enhance predictive toxicology tools using AI. This initiative further validates the real-world impact of the company’s platform.

Risks and Future Prospects

While Schrodinger’s AI-driven approach has significant potential, there are risks to consider. One key risk is the company’s dependence on collaborators for revenue growth. Many of its drug discovery revenues depend on milestones achieved through partnerships with pharmaceutical companies. If partners delay or cancel projects, it could impact Schrodinger’s financial performance.

Another challenge is the high cost of research and development. The company’s operating expenses increased 12% year-over-year in Q2 2024, primarily due to higher R&D investments. While this spending is essential for innovation, it also increases the company’s cash burn rate. Schrodinger’s current cash position of $381.5 million provides a financial cushion, but continuous investment in R&D means that the company will need to maintain strong revenue growth to sustain operations.

Stock volatility is another consideration. As a growth-oriented tech-healthcare stock, Schrodinger’s valuation is sensitive to market fluctuations and investor sentiment. AI-driven stocks, in particular, have experienced significant swings in valuation due to broader market conditions and changing investor risk appetites. Despite this, Schrodinger remains well-positioned in a sector that is poised for long-term expansion.

What Investors Should Consider

Schrodinger’s AI-powered platform positions it as a key player in computational drug discovery, an area poised for rapid expansion. With strong software adoption, increasing pharma partnerships, and a growing proprietary pipeline, SDGR could offer long-term value.

Short-term traders may find SDGR attractive due to its recent financial momentum. Long-term investors should consider its growth potential in AI-driven drug development, especially as the industry continues shifting toward computational approaches. Risk-tolerant biotech investors might view SDGR as a disruptive force with high upside potential, albeit with some financial uncertainties.

Given the company’s expanding AI capabilities, growing revenue streams, and industry tailwinds, Schrodinger is a stock worth watching in the evolving healthcare technology landscape. As AI continues to shape the future of drug discovery, Schrodinger’s position as an industry leader could make it a compelling choice for forward-looking investors.

The Digital Payments Boom: Why StoneCo (STNE) Could Surge

Posted on by The INO.com Team

Across emerging markets, the shift to digital payments is accelerating, driven by increased smartphone penetration, e-commerce growth, and government policies promoting financial inclusion. Brazil, Latin America's largest economy, is at the forefront of this transformation, with the instant payment system PIX gaining rapid adoption. PIX transactions exceeded 40 billion in 2023, highlighting the nation's move away from cash.

StoneCo Ltd. (STNE), a leading fintech company in Brazil, is strategically positioned to capitalize on this evolution. By focusing on small and medium-sized businesses (SMBs) through its digital financial services, StoneCo has become a key enabler of Brazil’s cashless transition. The company’s ability to leverage advanced technology to streamline payments and banking services makes it a strong contender in the fintech industry.

Fintech Adoption Among Small Businesses

Brazil’s SMB sector, which contributes nearly 30% of the country’s GDP, has been historically underserved by traditional banks. Fintech companies, including StoneCo, have stepped in to fill this gap. StoneCo’s third-quarter 2024 earnings report showed that its SMB total payment volume (TPV) grew 20% year-over-year to R$114 billion. This underscores the increasing reliance of small businesses on digital payment solutions.

Additionally, StoneCo’s banking services are gaining traction, with demand deposits reaching R$6.7 billion—a 50% increase compared to the previous year. This growth in deposits highlights a broader trend of SMBs shifting towards digital financial solutions for their banking needs. By offering a suite of services, including lending and financial management tools, StoneCo is creating a more comprehensive ecosystem for small business owners.

Competitive Dynamics in Latin America

Latin America’s digital payments sector is intensely competitive, with players such as MercadoLibre’s Mercado Pago and Brazil’s PagSeguro vying for market share. However, StoneCo has differentiated itself through an integrated financial ecosystem that includes payments, banking, and credit offerings.

One standout metric is StoneCo’s merchant credit portfolio, which grew by nearly 30% quarter-over-quarter to R$923 million. Unlike traditional lenders, StoneCo leverages transaction data to assess creditworthiness, reducing risk while offering accessible financing options to small businesses. This data-driven approach provides a competitive advantage in the region’s evolving fintech landscape. Additionally, the company’s strong relationships with merchants create opportunities for cross-selling new financial products, further deepening customer engagement.

StoneCo’s Strategic Moves

StoneCo has been proactive in expanding its offerings and partnerships. In Q3 2024, the company launched Giro Fácil, a revolving credit facility designed to support SMB cash flow needs. Furthermore, the company’s software division has successfully cross-sold financial services, with card total payment volume among software clients growing at twice the rate of its core SMB segment.

Another key development is StoneCo’s robust profitability metrics. The company’s adjusted net income surged 35% year-over-year to R$587 million, with an adjusted earnings per share (EPS) of R$1.97—an impressive 42.6% growth compared to Q3 2023. This financial strength has allowed StoneCo to execute a substantial R$1 billion share buyback program, enhancing shareholder value. Furthermore, the company has been actively optimizing its operational efficiency and reducing costs while expanding its customer base, which is crucial for long-term growth.

Risks and Considerations

Despite its strong growth trajectory, StoneCo faces challenges that investors should consider. The Brazilian real’s volatility could impact earnings, as foreign exchange fluctuations affect the company’s revenue when converted to U.S. dollars. Additionally, regulatory shifts in Brazil’s financial sector could influence transaction fees and lending operations.

Moreover, competition remains fierce. While StoneCo’s take rate—a key measure of revenue per transaction—hit a record 2.58% in Q3 2024, sustaining such margins in a competitive market will require continued innovation and customer acquisition. The company will also need to navigate evolving consumer behaviors, which may influence the adoption of alternative payment methods beyond traditional card transactions.

What Should Investors Do?

With Brazil’s digital payments sector expanding rapidly and StoneCo demonstrating strong financial performance, the stock presents an intriguing opportunity. Investors looking for exposure to Latin American fintech may find StoneCo appealing, particularly given its consistent revenue growth, expanding banking ecosystem, and improving profitability. However, they should also weigh currency risks and competitive pressures before making investment decisions.

For long-term investors, StoneCo's ongoing expansion and focus on operational efficiency make it a stock to watch. Monitoring upcoming earnings reports, regulatory developments, and competitive positioning will be crucial in assessing the stock’s long-term potential. With a strong foothold in Brazil’s growing digital economy, StoneCo remains well-positioned to thrive in the evolving fintech landscape.

The Next Big Step in Genomics: Why CRISPR Therapeutics (CRSP) Could Deliver

Posted on by The INO.com Team

The field of gene editing has seen remarkable advancements over the past decade, with CRISPR-Cas9 technology leading the way. CRISPR Therapeutics (CRSP), one of the foremost players in this space, has made significant strides in applying this groundbreaking technology to develop gene-based treatments for serious diseases. The company’s lead therapy, CASGEVY (exagamglogene autotemcel or exa-cel), developed in collaboration with Vertex Pharmaceuticals (VRTX), has gained regulatory approval in multiple regions, including the U.S., European Union, and Canada. This approval marks a significant step in bringing CRISPR-based therapies into mainstream medicine.

Beyond CASGEVY, CRISPR Therapeutics is advancing a broad pipeline that includes next-generation CAR-T cell therapies for cancer, in vivo gene-editing candidates, and regenerative medicine programs targeting diseases like Type 1 diabetes. These developments position the company at the forefront of the genomics revolution. As gene-editing technology becomes more refined and widely accepted, CRISPR Therapeutics is poised to become a major beneficiary, potentially transforming treatments for a variety of genetic disorders.

Market Overview

The global gene therapy market is expanding rapidly, with a projected compound annual growth rate (CAGR) of over 18.9% from 2024 through 2030. Advances in gene-editing tools, increased investment in biotech, and growing regulatory support are fueling this growth. With its CRISPR-based therapies, CRISPR Therapeutics is well-positioned to capitalize on this trend. The potential for gene-editing therapies to offer curative treatments for previously untreatable conditions is a key driver of market enthusiasm. Patients suffering from rare genetic diseases that previously had no viable treatment options may now have a chance for a better quality of life due to CRISPR-based innovations.

While CRISPR Therapeutics is a leader in the gene-editing sector, it faces competition from other biotech firms such as Editas Medicine (EDIT) and Intellia Therapeutics (NTLA). Additionally, larger pharmaceutical companies like Pfizer (PFE) and Novartis (NVS) are investing in gene therapies. However, CRISPR Therapeutics differentiates itself with a robust pipeline, strategic partnerships, and a first-mover advantage with the approval of CASGEVY. The competition is fierce, but CRISPR Therapeutics’ ability to execute clinical trials successfully and secure approvals has given it a strong foothold in this emerging industry. The company’s continued investment in R&D ensures that it remains at the cutting edge of gene-editing technology.

Why CRISPR Therapeutics?

In addition to CASGEVY, which treats sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), CRISPR Therapeutics is developing a range of therapies across multiple areas. The company’s CAR-T cell therapies, such as CTX112 and CTX131, target CD19 and CD70 for B-cell malignancies and solid tumors, respectively. Initial clinical trial results have demonstrated promising efficacy. The potential for these therapies to be more effective than traditional CAR-T treatments is significant, as they aim to enhance potency and minimize immune system rejection.

CRISPR Therapeutics is also investing in vivo gene editing with programs like CTX310 and CTX320, which target cardiovascular diseases. These programs leverage CRISPR’s proprietary lipid nanoparticle platform to edit genes in the liver. Cardiovascular diseases remain among the leading causes of death worldwide, and gene-editing treatments could provide a revolutionary approach to managing and potentially curing some of these conditions. If successful, these therapies could create entirely new treatment paradigms and provide long-term benefits for patients.

The company’s work in regenerative medicine, particularly with CTX211 for Type 1 diabetes, showcases its ambition to develop innovative solutions for chronic diseases. This stem cell-derived beta islet cell therapy is designed to enable insulin production without requiring chronic immunosuppression. The potential impact of such a therapy cannot be overstated, as it could significantly alter the landscape of diabetes treatment, reducing the dependency on insulin injections and improving long-term health outcomes for millions of patients.

A key strength of CRISPR Therapeutics is its strategic partnership with Vertex Pharmaceuticals. Under the terms of their agreement, Vertex handles the global development, manufacturing, and commercialization of CASGEVY, while CRISPR Therapeutics retains a 40% profit share. This partnership has already led to a $200 million milestone payment following the FDA approval of CASGEVY. Collaborations like these provide the company with financial stability and access to valuable industry expertise, increasing its chances of long-term success.

Risks and Financial Metrics

Despite its potential, investing in CRISPR Therapeutics carries risks. Clinical trial failures, regulatory setbacks, or safety concerns could impact its stock performance. The gene-editing industry is still in its early stages, and there is uncertainty surrounding the long-term efficacy and potential unintended consequences of CRISPR-based treatments. While the science is promising, investors must be aware of the inherent risks associated with pioneering medical technologies.

From a financial perspective, CRISPR Therapeutics reported a net loss of $85.9 million in Q3 2024, reflecting its continued investment in R&D. However, the company maintains a strong cash position of approximately $1.9 billion, providing ample runway for future developments. Having a substantial cash reserve is crucial for biotech firms, as it allows them to fund ongoing trials, develop new products, and navigate potential regulatory hurdles without immediate concerns about liquidity.

Investment Outlook

With a first-in-class CRISPR therapy already in the market, a robust pipeline, and strong financial backing, CRISPR Therapeutics presents a compelling opportunity for long-term investors. While volatility is expected, the company’s pioneering role in gene editing could lead to substantial returns as the field matures. Investors with a high-risk tolerance and a long-term perspective may find CRSP stock an attractive addition to their biotech portfolios.

For those interested in genomics, ETFs that include CRISPR Therapeutics among their holdings could provide a diversified approach to gaining exposure to this cutting-edge industry. As gene-editing technology continues to develop, closely monitoring regulatory milestones and clinical trial results will be key in evaluating CRISPR Therapeutics' long-term growth potential. The coming years could determine whether CRISPR-based therapies become standard medical treatments, and investors who position themselves early may stand to benefit significantly.